Start Over

Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection

Authors :: Chia-Yen Dai
Chung-Feng Huang
Yu-Fen Tsai
Ching-I Huang
Shih-Feng Cho
Yi-Chang Liu
Ya-Lun Ke
Ming-Lung Yu
Yuh-Ching Gau
Pey-Fang Wu
Hui-Ching Wang
Jeng-Shiun Du
Hui-Hua Hsiao
Chin-Mu Hsu
Tsung-Jang Yeh
Ching-I Yang
Tzer-Ming Chuang
Source :: Journal of Personalized Medicine, Volume 11, Issue 9, Journal of Personalized Medicine, Vol 11, Iss 844, p 844 (2021)
Publication Year :: 2021
Publisher :: Multidisciplinary Digital Publishing Institute, 2021.
Abstract: Background: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. Methods: A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. Results: A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivariate analysis, poor performance status (p &lt<br />0.001), advanced stage (p &lt<br />0.001), less chemotherapy cycles (p &lt<br />0.001), and the presence of liver toxicity (p = 0.001) contributed to poor OS in DLBCL. Among HCV-positive DLBCL, the severity of liver fibrosis was the main risk factor related to death. Conclusion: Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.